Sevelamer Dosing for Hyperphosphatemia in Adults
For adults with hyperphosphatemia on dialysis, start sevelamer at 800-1600 mg three times daily with meals based on baseline serum phosphorus, titrate by one tablet per meal every 2 weeks to achieve serum phosphorus ≤5.5 mg/dL, with a maximum studied dose of 13 g/day. 1
Starting Dose Selection
The initial dose depends on your patient's baseline serum phosphorus level 1:
- Serum phosphorus >5.5 and <7.5 mg/dL: Start 800 mg (one 800 mg tablet or two 400 mg tablets) three times daily with meals
- Serum phosphorus ≥7.5 and <9 mg/dL: Start 1600 mg (two 800 mg tablets or four 400 mg tablets) three times daily with meals
- Serum phosphorus ≥9 mg/dL: Start 1600 mg (two 800 mg tablets or four 400 mg tablets) three times daily with meals
If switching from calcium acetate, use approximately mg-for-mg conversion: 1 tablet of calcium acetate 667 mg = 800 mg sevelamer (or 1600 mg sevelamer for 2 tablets calcium acetate, etc.) 1
Dose Titration Protocol
Adjust the dose every 2 weeks based on serum phosphorus response 1:
- If serum phosphorus >5.5 mg/dL: Increase by one tablet per meal (2400 mg/day increment)
- If serum phosphorus 3.5-5.5 mg/dL: Maintain current dose
- If serum phosphorus <3.5 mg/dL: Decrease by one tablet per meal
The average effective dose in Phase 3 trials was approximately three 800 mg tablets per meal (7200 mg/day total). The maximum studied daily dose is 13 g/day 1. In real-world studies, mean doses ranged from 2.4-7.1 g/day depending on severity of hyperphosphatemia 2, 3, 4.
Clinical Context and Rationale
Sevelamer is particularly indicated when calcium-based binders are contraindicated or problematic 5. The K/DOQI guidelines recommend sevelamer as primary therapy in dialysis patients (CKD Stage 5) with 5:
- Hypercalcemia (corrected calcium >10.2 mg/dL)
- Severe vascular or soft-tissue calcification
- PTH levels <150 pg/mL on two consecutive measurements
- Total elemental calcium intake from binders exceeding 1500 mg/day
Importantly, sevelamer is only FDA-approved for dialysis patients—safety and efficacy have not been established in non-dialysis CKD patients 1. This contrasts with calcium-based binders which can be used in CKD stages 3-4 5.
Target Phosphorus Levels
Your phosphorus targets should guide titration 5, 6:
- CKD Stage 5 (dialysis patients): 3.5-5.5 mg/dL
- CKD Stages 3-4: 2.7-4.6 mg/dL (though sevelamer not studied in this population)
The 2017 KDIGO update suggests lowering elevated phosphate toward the normal range rather than strict normalization 6.
Administration Considerations
Sevelamer must be taken with meals to bind dietary phosphate effectively 1. The tablets should be swallowed whole—crushing is not recommended per FDA labeling due to risk of esophageal retention and feeding tube obstruction, though one retrospective study suggested crushed tablets may be feasible with proper protocols 1, 7.
Common Pitfalls to Avoid
Do not use sevelamer in patients with bowel obstruction (absolute contraindication) or those with severe GI motility disorders, dysphagia, or history of major GI surgery 1. Cases of bowel obstruction, perforation, and esophageal retention have been reported.
Monitor for metabolic acidosis and vitamin deficiencies. Sevelamer can reduce bicarbonate levels and decrease absorption of fat-soluble vitamins (D, E, K) and folic acid 1. Most dialysis patients receive vitamin supplementation, which should continue.
The high pill burden is a major adherence challenge—patients may need to take 6-12 large tablets daily. This reality must be discussed upfront, as poor adherence will result in treatment failure 5.
Additional Benefits
Beyond phosphate control, sevelamer significantly reduces LDL cholesterol (by 30-35%) and total cholesterol compared to calcium-based binders 5, 2. In the landmark trial cited in K/DOQI guidelines, sevelamer prevented progression of coronary and aortic calcification while calcium-based binders showed significant progression 5.